IBIO, INC.

IBIO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $100.0K $400.0K $225.0K $0 $1.9M $2.4M $1.6M $2.0M
Cost of Revenue $216.0K $1.5M $703.0K
Gross Profit $2.2M $909.0K $935.0K
Gross Margin 115.0% 38.3% 57.1%
Operating Expenses
Research & Development $19.6M $8.3M $5.2M $10.3M $9.8M $10.0M $3.6M $5.5M
SG&A Expense $10.6M $10.7M $11.7M $19.0M $21.8M $22.0M $11.4M $12.3M
Operating Income $-35.1M $-18.6M $-16.6M $-29.3M $-29.7M $-31.1M $-14.0M $-15.8M
Operating Margin -35,141.0% -4,650.5% -7,392.9% -1,576.3% -1,312.1% -854.9% -782.4%
Interest Expense $83.0K $1.4M $2.5M $2.5M $1.9M
Pretax Income $-33.0M $-18.4M
Income Tax Expense $0 $0 $0 $0 $0 $0 $0 $0
Net Income $-33.0M $-18.4M $-24.9M $-65.0M $-50.3M $-23.2M $-16.4M $-17.6M
Net Margin -33,044.0% -4,594.3% -11,069.8% -2,670.0% -978.8% -1,003.6% -871.8%
EPS (Basic) $-0.32 $-0.18 $-0.22 $-0.59 $-0.03 $-0.02 $0.00 $-0.01
EPS (Diluted) $-0.32 $-0.18 $-0.22 $-0.59 $-0.03 $-0.02 $0.00 $-0.01
Shares Outstanding (Basic) 104.1M 105.0M 114.9M 110.2M 1.57B 1.41B 32.45B 4.35B
Shares Outstanding (Diluted) 104.1M 105.0M 114.9M 110.2M 1.57B 1.41B 32.45B 4.35B
Dividends Per Share
← Newer Page 1 of 2 Older →